169 related articles for article (PubMed ID: 23743566)
1. Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution.
Semino-Mora C; Testerman TL; Liu H; Whitmire JM; Studeman K; Jia Y; McAvoy TJ; Francis J; Nieroda C; Sardi A; Merrell DS; Dubois A
Clin Cancer Res; 2013 Jul; 19(14):3966-76. PubMed ID: 23743566
[TBL] [Abstract][Full Text] [Related]
2. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
Semino-Mora C; Liu H; McAvoy T; Nieroda C; Studeman K; Sardi A; Dubois A
Ann Surg Oncol; 2008 May; 15(5):1414-23. PubMed ID: 18299935
[TBL] [Abstract][Full Text] [Related]
3. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
4. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei".
Ronnett BM; Zahn CM; Kurman RJ; Kass ME; Sugarbaker PH; Shmookler BM
Am J Surg Pathol; 1995 Dec; 19(12):1390-408. PubMed ID: 7503361
[TBL] [Abstract][Full Text] [Related]
5. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis.
Ronnett BM; Yan H; Kurman RJ; Shmookler BM; Wu L; Sugarbaker PH
Cancer; 2001 Jul; 92(1):85-91. PubMed ID: 11443613
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of single isolated cells with decreased E-cadherin expression in pseudomyxoma peritonei.
Koh YW; Jun SY; Kim KR
Pathol Int; 2014 Apr; 64(4):164-72. PubMed ID: 24750186
[TBL] [Abstract][Full Text] [Related]
7. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
8. [Histologic classification and prognostic implication of pseudomyxoma peritonei].
Guo AT; Wei LX; Song X
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):474-9. PubMed ID: 17845762
[TBL] [Abstract][Full Text] [Related]
9. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei.
Ronnett BM; Seidman JD
Am J Surg Pathol; 2003 May; 27(5):650-7. PubMed ID: 12717249
[TBL] [Abstract][Full Text] [Related]
10. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review.
Bradley RF; Stewart JH; Russell GB; Levine EA; Geisinger KR
Am J Surg Pathol; 2006 May; 30(5):551-9. PubMed ID: 16699309
[TBL] [Abstract][Full Text] [Related]
11. Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients.
Jackson SL; Fleming RA; Loggie BW; Geisinger KR
Mod Pathol; 2001 Jul; 14(7):664-71. PubMed ID: 11454998
[TBL] [Abstract][Full Text] [Related]
12. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
[TBL] [Abstract][Full Text] [Related]
13. Treating pseudomyxoma peritonei without heated intraperitoneal chemotherapy--a first look in New Zealand.
Wheeler BR; Reddy SK; Kenwright D; Keating JP
N Z Med J; 2014 Feb; 127(1389):31-9. PubMed ID: 24548955
[TBL] [Abstract][Full Text] [Related]
14. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Yan H; Pestieau SR; Shmookler BM; Sugarbaker PH
Mod Pathol; 2001 Mar; 14(3):164-71. PubMed ID: 11266521
[TBL] [Abstract][Full Text] [Related]
15. Commentary on 'Survival of patients with pseudomyxoma peritonei treated by serial debulking'.
Moran BJ
Colorectal Dis; 2010 Sep; 12(9):872-3. PubMed ID: 20718839
[No Abstract] [Full Text] [Related]
16. [Pseudomyxoma peritonei--a case report].
Iarŭmov N; Terziev I; Toshev S; Angelov K; Velev G; Todorov G; Koĭchev A; Ilinov V
Khirurgiia (Sofiia); 2006; (3):15-9. PubMed ID: 18788112
[TBL] [Abstract][Full Text] [Related]
17. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei.
Deraco M; Gronchi A; Mazzaferro V; Inglese MG; Pennacchioli E; Kusamura S; Rizzi M; Anselmi RA; Vaglini M
Tumori; 2002; 88(5):370-5. PubMed ID: 12487553
[TBL] [Abstract][Full Text] [Related]
19. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process.
Mohamed F; Gething S; Haiba M; Brun EA; Sugarbaker PH
J Surg Oncol; 2004 Apr; 86(1):10-5. PubMed ID: 15048674
[TBL] [Abstract][Full Text] [Related]
20. COX-2 expression in pseudomyxoma peritonei.
Gatalica Z; Loggie B
Cancer Lett; 2006 Nov; 244(1):86-90. PubMed ID: 16427185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
